Aim We present a high-performance liquid chromatography (HPLC) method, suitable for the analysis of epirubicin and its metabolite epirubicinol in saliva and plasma. Methods Preparation of saliva and plasma samples was performed by extraction of analytes with a chloroform : 2-propanol mixture (6:1, v/v) and evaporation of the organic phase to dryness under vacuum at a temperature of approximately 45 °C. The chromatographic analysis was carried out by reversed-phase isocratic elution of the anthracyclines with a Chromsep Stainless Steel HPLC column (150 x 4.6 mm I.D.) filled with Nucleosil 100 S C18 material, particle size 5 µm. Results The detection was accomplished by spectrofluorimetry at excitation and emission wavelengths of 474 and 551 nm respectively. The anthracyclines eluted within 10 min of injection and the method appeared to be specific. The method is linear over a concentration range of 5 -1000 µg/L for epirubicin and 2 -400 µg/L for epirubicinol (r > 0.99) in both saliva and plasma. The recoveries from saliva and plasma of epirubicin, epirubicinol and the internal standard doxorubicin were 88.9 and 69.0%, 87.6 and 77.3% and 80 and 67.9 % respectively. The lower limit of quantitation was 5 µg/L for epirubicin and 2 µg/L for epirubicinol. The method proved to be precise and accurate, as the within-day and between-day coefficients of variation were less than 10 %. Conclusions Overall results indicate that our method is suitable for the bioanalysis of epirubicin and epirubicinol in saliva as well as plasma.
Introduction
Anthracyclines are widely used as antitumor agents and are effective against a broad range of malignancies [1] . The first identified anthracyclines, daunorubicin and doxorubicin, were isolated from pigment producing Streptomyces species in the early 1960s and remain in widespread clinical use today [2] . Epirubicin is the 4'-epimer of doxorubicin and has an antitumor spectrum that is similar to doxorubicin, but produces less side effects [1, 3, 4] . Clinically epirubicin has shown therapeutic activity in patients with breast cancer, malignant lymphomas, sarcomas, lung, ovarian and prostate cancer [1, 3, 5] . Myelosuppression is the major acute dose-limiting toxicity, while cardiotoxicity is the most important chronic cumulative dose-limiting toxicity [1, 3, 6] . Other side effects are nausea, vomiting, alopecia, diarrhoea, phlebitis and mucositis [1, 3] . The relationship between salivary exposure of cytotoxic drugs and the occurrence of gastrointestinal side effects has so far given little attention. Salivary excretion has been described for cisplatin [6] , carboplatin [7, 8] , cytarabin [9] , doxorubicin [5, 10] , fluorouracil [11, 12] , etoposide [13, 14] , irinotecan [15] , melphalan [16] , methotrexate [17] [18] [19] [20] [21] [22] [23] , paclitaxel [24] and teniposide [25] . For most of these agents, huge interindividual differences in saliva/plasma concentration ratios (S/P ratio) were found. This is caused by many variables influencing the excretion of drugs into saliva. The transfer of drugs from blood into saliva depends upon the (physico-)chemical properties of the compound such as molecular size, lipid solubility, pKa and protein binding. The primary physiologic factors affecting salivary distribution are salivary pH, salivary flow rate and existing pathology of the oral cavity [26] . The salivary excretion of chemotherapeutic agents in relation to gastrointestinal side effects has so far only been studied for fluorouracil and methotrexate. Excretion of fluorouracil and 7-hydroxymethotrexate into saliva were reported to be positively related to the development of mucositis [12, 17, 18, [20] [21] [22] [23] . Although several methods have been published regarding the analysis of anthracyclines in plasma, as far as we know a validated assay for determination of these compounds in saliva has never been reported. Celio et al. [4] and Bresolle et al. [10] studied the salivary excretion of doxorubicin, but did not provide details on the analytical methods in their reports. In this paper we describe a validated HPLC method for determining epirubicin and its metabolite epirubicinol in saliva, which is also suitable for analysis of anthracyclines in plasma.
Methods

Chemicals
Epirubicin hydrochloride (purity 98.4 %) and epirubicinol hydrochloride (purity 78 %) were obtained from Pharmacia & Upjohn, Milano, Italy. Doxorubicin hydrochloride (purity 97.9 %) was purchased from Rhône-Poulenc Pharma, Hoevelaken, the Netherlands. All other chemicals were of standard analytical grade. Borax buffer consisted of 16.4 g/L disodium tetraborate · 10 H 2 O in water, adjusted to pH 9 with a 0.1 M hydrochloric acid solution.
High Performance Liquid Chromatography system
The HPLC system consisted of a Spectroflow 400 solvent delivery system (ABI Analytical Kratos Division, Ramsey NJ, USA), a Waters 717 + autosampler (Waters, Maryland, MA), a Shimadzu fluorescence detector FR10AXL (Shimadzu, Kyoto, Japan), a computer equipped with Chrom Perfect 32 (version 3.5) Chromatography data integration system (Justice Innovations Inc. Palo Alto, CA). The analytical column used for the validation was a Chromsep Stainless Steel HPLC column (150 x 4.6 mm I.D.) filled with Nucleosil 100 S C18 material, particle size 5 µm (Chrompack, Middelburg, the Netherlands). The mobile phase consisted of water : 0.1 M orthophosphoric acid : triethylamine : acetonitril (70 : 3 : 0.07 : 27, v/v). Before the acetonitril was added the mixture was adjusted to pH 2.8 with 6 M hydrochloride acid solution. The pump was set at a flow rate of 1.5 mL/min. The excitation wavelength of the fluorescence detector was set at 474 nm, the emission wavelength was set at 551 nm. The injection volume was 50 µL.
Preparation of standards
For each compound, except for doxorubicin (internal standard), two independent stock solutions were prepared. One was used for the preparation of the calibration samples and the second for the preparation of the validation samples. The stock solutions of epirubicin and epirubicinol were prepared by dissolving epirubicin(ol) hydrochloride in methanol in a 25.0 mL (polypropylene) volumetric flask to obtain a concentration of 200 mg/L epirubicin(ol) free base. Calibration samples were prepared by adding the required amount of the stock solutions to human saliva or plasma to obtain concentrations of 5, 10, 
Sample preparation
The extraction procedure was based on a method previously described by Oosterbaan et al. [28] . Frozen (-20 °C) saliva or plasma samples (validation or patient samples) were thawed and sonificated for 15 min before analysis. An aliquot of 0.5 mL of saliva or plasma sample was mixed with 100 µL of doxorubicin working solution in a 10 mL polypropylene tube. To plasma samples additionally 100 µL of a solution of 0.2 M calcium chloride was added and samples were allowed to stand for 15 min. Subsequently, to both saliva and plasma samples, 0.5 mL of borax buffer pH 9 was added and the samples were extracted with 7 mL of extraction solvent (chloroform: 2-propanol mixture 6:1 v/v) by shaking on a rotary mixer for 20 minutes, at a speed of 40 rpm. After centrifugation at 2800 g for 5 min the upper (aqueous) layer was discarded and the remaining organic phase was transferred to a clean polypropylene tube. To the extracts from saliva samples, subsequently 100 µL of propyleneglycol (10 %) in ethanol was added. The solvent was evaporated to dryness in a vacuum evaporator at a temperature of approximately 45 ºC. The residue was reconstituted in 200 µL of the mobile phase and 50 µL was injected into the chromatographic system. Extracts from plasma were mixed with 200 µL of 0.1 M phosphoric acid and the sample was extracted by shaking on the rotary mixer for 20 min, at a speed of 50 rpm. After centrifugation at 2800 g for 5 min 50 µL of the upper aqueous layer was injected into the chromatographic system.
Patient samples and blanks
Patient plasma and saliva samples were obtained from a patient who participated in a randomized multicenter phase III trial comparing gemcitabine in combination with either cisplatin of epirubicin as first-line treatment in advanced non-small cell lung cancer [27] . The protocol was approved by the Medical Ethics Review Committee of the University Hospital Groningen and the patient gave written informed consent. Chemotherapy on the first day of treatment consisted of gemcitabine 1125 mg/m 2 as a 30 min infusion immediately followed by epirubicin 100 mg/m 2 as bolus injection. Collection of blood and saliva samples was started immediately after the epirubicin dose and continued until 192 h after bolus injection. The samples were placed on ice immediately after collection. Subsequently, plasma and untreated saliva samples were kept frozen at -20 °C until analysis. Blank saliva samples for method validation were obtained from male and female volunteers. The ratio of saliva and plasma concentration (S/P ratio) was calculated for the samples collected at the same time point.
Calibration
For the validation of the method a calibration curve was prepared in the range of 5-1000 ng/mL for epirubicin and 2-400 ng/mL for epirubicinol respectively. The parameters of the calibration curves were calculated by weighted linear regression and were used to calculate the epirubicin and epirubicinol concentrations of the validation samples. The peak height ratios (epirubicin/internal standard and epirubicinol/internal standard) were taken as the responses for a given sample.
Validation
The method was validated on linearity, accuracy, recovery, freeze-thaw stability, sample compartment stability and sample dilution. On day one the linearity of the calibration curves and the stability in the sample compartment were determined. On the days two to six precision and accuracy, recovery, freeze/thaw stability and dilution of samples were tested. During validation six blank samples obtained from six different human volunteers were tested to demonstrate that there were no interfering components. The results of the tests were evaluated against international used acceptance criteria described by Shah et al. [29] .
Linearity
To evaluate linearity of the calibration curves three calibration curves were prepared and analysed. The curves were judged linear if the correlation coefficient r was better than 0.99 as calculated by weighted linear regression. The goodness of fit and the lack of fit were determined by means of ANOVA calculations.
Accuracy and precision
To assess the accuracy and precision of the method, the samples LLQ, low, medium and high were analysed three times a day, during five days. The coefficients of variation (CV %) for the within-day precision and the coefficients of variation for the between-day precision were estimated by ANOVA. An overall coefficient of variation less than 20 % was accepted for the LLQ of this method. For the samples with low, medium and high concentration an overall coefficient of variation less than 15 % was accepted [29] . Accuracy was calculated from the mean of the amount observed and the theoretical concentrations at a particular level. The method was considered accurate when the deviation from the theoretical concentration (bias) was less than 20 % at the LLQ level and less than 15 % at the remaining levels [29] .
Recovery
The recoveries of epirubicin, epirubicinol and doxorubicin were determined by comparing the peak heights of the validation samples low, medium and high with the peak heights of analysed solutions containing all the compounds of interest at a concentration corresponding with 100 % recovery [29] .
Freezing and thawing
To assess freezing and thawing stability samples with a low concentration and samples with a high concentration were prepared . The same sample was frozen and thawed each day for five days. After each freeze/thaw cycle the samples were analysed in triplicate. Bias was calculated in the same way as with precision and accuracy. Samples were considered stable if bias was below 10 % after five freeze/thaw cycles.
Dilution
Because some samples of clinical patients can have concentrations above the higher limit of quantitation (HLQ), these samples have to be diluted to obtain concentrations within the calibration range. In order to validate the dilution of samples the following experiment was carried out: samples with a concentration of 2.5 mg/L epirubicin and 1 mg/L epirubicinol respectively were diluted 5 times and samples with a concentration of 10 mg/L epirubicin and 4 mg/L epirubicinol respectively were diluted 20 times to obtain concentrations of 500 µg/L epirubicin and 200 µg/L epirubicinol. Blank human saliva was used as diluting agent. These diluted samples were analysed in triplicate, during five days. Bias was calculated by ANOVA. Dilution was considered possible if bias was below 10 %.
Stability during storage in sample compartment
Stability during storage in sample compartment was determined by analysing samples with low and high concentration over a period of 30 h. The calculated response at t = 30 h was compared to the calculated response at t = 0 h. Samples were judged stable over a
Results
Retention times
The retention times of epirubicinol, doxorubicin and epirubicin were 5.60 ± 0.39, 7.52 ± 0.49 and 9.66 ± 0.66 min (all based on n=265) respectively. No interfering peaks were observed in the chromatograms.
Linearity
The analysis of the detector response as a function of analyte concentration in calibration standards in the range of 5-1000 µg/L for epirubicin and 2-400 µg/L for epirubicinol gave a correlation coefficients better than 0.99 for epirubicin and epirubicinol in saliva (figure 1). In plasma also correlation coefficients better than 0.99 were found for both compounds. The lack of fit test turned out significant for epirubicin in both saliva and plasma as well as for epirubicinol in plasma. For epirubicinol in saliva no significant lack of fit was calculated. 
Accuracy and precision
In saliva as well as plasma, overall coefficients of variation were below 20 % for LLQ and below 15 % for low, medium and high concentrations for both epirubicin and epirubicinol (tables 1-4).
Recovery
In saliva, the mean calculated recoveries of epirubicin for the low, medium and high concentrations were 92.6 %, 86.6 % and 87.6 % respectively. For epirubicinol these recoveries were 85.8 %, 89.1 % and 88.0 %. For doxorubicin a recovery of 80.0 % was found. In plasma, the mean calculated recoveries of epirubicin for the low, medium and high concentrations were 75.0 %, 63.8 % and 69.0 %. For epirubicinol these recoveries were 86.2 %, 72.8 % and 73.0 % respectively. For doxorubicin in plasma a recovery of 67.9 % was found.
Freezing and thawing
In saliva, bias was below 10 % for both low and high concentrations of epirubicin and epirubicinol. In plasma bias was below 10 % for both low and high concentrations of epirubicinol as well as for high concentrations epirubicin, but above 10 % for low epirubicin concentrations. Detailed results are represented in table 1 and 2 for epirubicin and epirubicinol respectively in saliva and table 3 and 4 for epirubicin and epirubicinol in plasma.
Figure 2 Chromatograms of blank saliva and blank plasma
Dilution
In saliva as well as plasma, bias was below 10 % for both low and high concentrations. Detailed results are represented in tables 1-4.
Stability during storage in sample compartment
For epirubicin in saliva the ratio decreased 6.1 % after 30 h for low concentration and 3.1 % for high concentrations. For epirubicinol the ratio decreased 1.1 % after 30 h for low concentration and 2.4 % for high concentrations. In plasma the ratio for epirubicin decreased 1.8 % after 30 h for low concentration and 0.2 % for high concentrations. For epirubicinol in plasma these ratios were 3.0 % for low concentrations and 0.4 % for high concentrations in plasma.
Patient's saliva. During validaton six blank samples were tested. None of the samples showed interfering peaks. An example of a blank saliva sample is given in figure 2 . Figure 3 shows a chromatogram of saliva from a patient, 6 h after a bolusinjection of 100 mg/m 2 epirubicin. Figure 4 depicts the saliva and saliva curves in the same patient. The theoretical S/P ratio of epirubicin was calculated with the following formula:
According to literature, the pKa of epirubicin is 7.7, the fraction unbound in plasma approximately 0.23, and the fraction unbound in saliva 1.00. Hence, the theoretical S/P ratio of epirubicin ranges from 0.23 to 3.92 when saliva pH decreases from 7.4 to 6. In the patient, epirubicin S/P ratios ranging from 0.002 to 2.56 were measured (see table 5 ). The lowest values were measured during the distribution phase shortly after bolus injection, during rapid decline of epirubicin plasma levels.
Discussion
In this paper we demonstrate that epirubicin and its metabolite epirubicinol can be measured in saliva over a wide range of concentrations (5-1000 µg/L for epirubicin and 2-400 µg/L for epirubicinol respectively) with high linearity and precision. This range is wide enough to cover saliva levels of epirubicin and epirubicinol in clinical practice. In a study with doxorubicin, Bressolle et al. [10] reported parotid saliva levels ranging from 11.7 to 82.6 µg/L following intravenous doses of 28-72 mg/m 2 doxorubicin. Celio et al. [5] found a range of 11.6 to 36.0 µg/L for doxorubicin in parotid saliva following an intravenous total dose of 50-90 mg. Surprisingly, a lack of fit was calculated for the linearity of the epirubicin calibration curve, despite a high correlation coefficient. We analysed that a very small variance in the triplicates, compared to the deviations of the individual points from the calibration line caused this lack of fit. Therefore, we considered the outcome of this statistical test in this case as irrelevant. We calculated a lower limit of quantification of 5 µg/L for epirubicin and 2 µg/L for epirubicinol in saliva. As far as we know, the lowest limit of quantitation mentioned in literature for analysis of anthracyclines in saliva by HPLC is 25 µg/L, although analytical results as low as 11.6 µg/L doxorubicin in saliva have been reported [5, 10] . Despite the fact that epirubicin and doxorubicin are chemically not fully identical, we believe that our method is at least 2.5-5 times more sensitive than previously reported methods for analysis of anthracyclines in saliva. As the extraction recovery at low concentrations is only marginally higher than that of doxorubicin (93% vs. 80%) and the relative emission intensities of epirubicin and doxorubicin during fluorospectroscopy are more or less identical, these factors do not explain improved sensitivity. Sample size, sample concentration, peak shape, signal to noise ration, and/or injection volume might be relevant parameters, but this was not further investigated. We measured recoveries of 88.9 %, 87.6 % and 80 % for epirubicin, epirubicinol and doxorubicin in saliva respectively at intermediate concentration levels. Although these recoveries are lower than those mentioned by Celio et al. [5] (95%), they appear to be very reproducible. The extraction procedure according to Oosterbaan et al. [28] , which was initially applied, produced recoveries of only 24%, 57% and 27% for epirubicin, epirubicinol and doxorubicin. Subsequently, several attempts have been made to improve the recovery from saliva, including solid phase extraction, sequential addition of isopropanol and chloroform, protein denaturation with acetonitril before extraction, concentration and pH variations in extraction buffer, variations in CaCl 2 concentration and addition of propylene glycol. The use of propylene glycol produced an acceptable increase in the recovery of epirubicin and epirubicinol, which could be explained by the prevention of sublimation or adsorption of the analytes during the evaporation step.
Freezing and thawing of samples, sample dilution, and storage of samples in a autosampler sample compartment were all considered acceptable according to Shah's criteria for accuracy and precision [29] . The saliva/plasma (S/P) ratios measured in our patient were in line with theoretical values. The S/P ratios increased significantly with time after dosing. This is in line with earlier findings of Bresolle et al. [10] for doxorubicin and doxorubicinol. The largest increase of S/P ratio occurred during the hours immediately after injection, largely due to rapidly decreasing epirubicin plasma levels as a result of extensive drug distribution. We conclude that the method for determination of anthracyclines in saliva, presented in this paper, has a lower limit of quantification than previously reported methods and is applicable over a wide concentration range. With slight modifications, this method can also be used for determination of anthracyclines in plasma. With concurrent analysis of anthracyclines in plasma and saliva, the extent of drug excretion into saliva can be studied and S/P ratios can be calculated.
